On July 9, 2018 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), reported that it will host a webcast on July 10, 2018 at 8:00 AM ET (Press release, Actinium Pharmaceuticals, JUL 9, 2018, View Source [SID1234527628]). The webcast will discuss the Company’s previously announced Actimab-A MRD clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD). Dr. Joseph Jurcic, Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center and Dr. Mark Berger, Chief Medical Officer and Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, Inc. will lead the webcast.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Participation and registration information is as follows:
Date: July 10,2018
Time: 8:00 AM ET
Registration Link: View Source
Telephone participation: U.S./Canada Toll Free: (855) 698-6739 or (646) 402-9440
Conference ID:2540
PIN Number: A Pin will be provided in the confirmation email received upon registration.
The Actimab-A MRD trial will study the safety/tolerability of Actinium’s Actimab-A in the postremission consolidation setting and include a dose finding analyses. The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The investigational new drug (IND) application for this trial has been cleared by the FDA.
About Actimab-A
Actimab-A is an antibody radio-conjugate (ARC) comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225. CD33 is a marker expressed on AML cells of virtually all affected patients. Actimab-A has been studied in over 100 patients to date and is the only CD33 targeting agent being studied in a broad range of diseases in which the CD33 antigen is expressed, including AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium-225 is highly differentiated radioisotope that emits high amounts of energy through the release of four alpha-particles that can cause double-stranded breaks in DNA with known resistance mechanisms to Actinium-225. Given the limited distance of its energy in the body, it is potentially sparing of non-targeted cells leading to better tolerability and less toxicities.
Actimab-A has been granted Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for newly diagnosed AML in patients age 60 and above.